WO2002096927A3 - Ribozyme based treatment of female reproductive diseases - Google Patents

Ribozyme based treatment of female reproductive diseases Download PDF

Info

Publication number
WO2002096927A3
WO2002096927A3 PCT/US2002/017674 US0217674W WO02096927A3 WO 2002096927 A3 WO2002096927 A3 WO 2002096927A3 US 0217674 W US0217674 W US 0217674W WO 02096927 A3 WO02096927 A3 WO 02096927A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
female reproductive
nucleic acid
growth factor
acid molecules
Prior art date
Application number
PCT/US2002/017674
Other languages
French (fr)
Other versions
WO2002096927A2 (en
Inventor
Jaime Escobedo
James Mcswiggen
Pamela Pavco
Dan Stinchcomb
Jennifer Sandberg
Gilad Gordon
Original Assignee
Ribozyme Pharm Inc
Chiron Corp
Jaime Escobedo
James Mcswiggen
Pamela Pavco
Dan Stinchcomb
Jennifer Sandberg
Gilad Gordon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/138,674 external-priority patent/US7034009B2/en
Application filed by Ribozyme Pharm Inc, Chiron Corp, Jaime Escobedo, James Mcswiggen, Pamela Pavco, Dan Stinchcomb, Jennifer Sandberg, Gilad Gordon filed Critical Ribozyme Pharm Inc
Priority to AU2002344237A priority Critical patent/AU2002344237B8/en
Priority to EP02752028A priority patent/EP1390385A4/en
Priority to CA002448320A priority patent/CA2448320A1/en
Priority to JP2003500106A priority patent/JP2005500025A/en
Priority to US10/287,949 priority patent/US20040102389A1/en
Priority to US10/306,747 priority patent/US20030216335A1/en
Publication of WO2002096927A2 publication Critical patent/WO2002096927A2/en
Priority to PCT/US2003/005022 priority patent/WO2003070910A2/en
Priority to AU2003216323A priority patent/AU2003216323B2/en
Priority to EP03742833A priority patent/EP1521768A4/en
Priority to GB0427955A priority patent/GB2406569B/en
Priority to GB0404898A priority patent/GB2396864B/en
Priority to CA002456444A priority patent/CA2456444A1/en
Priority to JP2003569803A priority patent/JP2005517436A/en
Publication of WO2002096927A3 publication Critical patent/WO2002096927A3/en
Priority to US10/665,951 priority patent/US20040138163A1/en
Priority to US10/664,668 priority patent/US20070203333A1/en
Priority to US10/670,011 priority patent/US20040209832A1/en
Priority to US10/683,990 priority patent/US20040198682A1/en
Priority to US10/712,633 priority patent/US20040220128A1/en
Priority to US10/726,236 priority patent/US20040142895A1/en
Priority to US10/758,155 priority patent/US20050075304A1/en
Priority to US10/764,957 priority patent/US20050054596A1/en
Priority to GBGB0404461.6A priority patent/GB0404461D0/en
Priority to US10/831,620 priority patent/US20050148530A1/en
Priority to US10/844,076 priority patent/US7176304B2/en
Priority to US10/922,761 priority patent/US20050267058A1/en
Priority to JP2008148548A priority patent/JP2009000105A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)

Abstract

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.
PCT/US2002/017674 1995-10-26 2002-05-29 Ribozyme based treatment of female reproductive diseases WO2002096927A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
AU2002344237A AU2002344237B8 (en) 2001-05-29 2002-05-29 Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions
EP02752028A EP1390385A4 (en) 2001-05-29 2002-05-29 Nucleic acid based modulation of female reproductive diseases and conditions
CA002448320A CA2448320A1 (en) 2001-05-29 2002-05-29 Ribozyme based treatment of female reproductive diseases
JP2003500106A JP2005500025A (en) 2001-05-29 2002-05-29 Nucleic acid-based regulation of female reproductive diseases and conditions
US10/287,949 US20040102389A1 (en) 1995-10-26 2002-11-04 Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US10/306,747 US20030216335A1 (en) 2001-11-30 2002-11-27 Method and reagent for the modulation of female reproductive diseases and conditions
JP2003569803A JP2005517436A (en) 2002-02-20 2003-02-20 RNA interference-mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acids (siNA)
PCT/US2003/005022 WO2003070910A2 (en) 2002-02-20 2003-02-20 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA002456444A CA2456444A1 (en) 2002-02-20 2003-02-20 Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina)
AU2003216323A AU2003216323B2 (en) 2002-02-20 2003-02-20 Inhibition of vascular endothelial growth factor (vegf) and vegf receptor gene expression using short interfereing nucleic acid (sina)
EP03742833A EP1521768A4 (en) 2002-02-20 2003-02-20 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
GB0427955A GB2406569B (en) 2002-02-20 2003-02-20 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfe
GB0404898A GB2396864B (en) 2002-02-20 2003-02-20 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression
US10/665,951 US20040138163A1 (en) 2002-05-29 2003-09-18 RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/664,668 US20070203333A1 (en) 2001-11-30 2003-09-18 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/670,011 US20040209832A1 (en) 2001-11-30 2003-09-23 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/683,990 US20040198682A1 (en) 2001-11-30 2003-10-10 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US10/712,633 US20040220128A1 (en) 1995-10-26 2003-11-13 Nucleic acid based modulation of female reproductive diseases and conditions
US10/726,236 US20040142895A1 (en) 1995-10-26 2003-12-02 Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US10/758,155 US20050075304A1 (en) 2001-11-30 2004-01-12 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/764,957 US20050054596A1 (en) 2001-11-30 2004-01-26 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
GBGB0404461.6A GB0404461D0 (en) 2001-05-29 2004-02-27 Ribozyme based treatment of female reproductive diseases
US10/831,620 US20050148530A1 (en) 2002-02-20 2004-04-23 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/844,076 US7176304B2 (en) 2002-02-20 2004-05-11 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/922,761 US20050267058A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
JP2008148548A JP2009000105A (en) 2002-02-20 2008-06-05 RNA INTERFERENCE-MEDIATED INHIBITION OF VASCULAR ENDOTHELIUM GROWTH FACTOR AND VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID(siNA)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87016101A 2001-05-29 2001-05-29
US09/870,161 2001-05-29
US33446101P 2001-11-30 2001-11-30
US60/334,461 2001-11-30
US10/138,674 US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US10/138,674 2002-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/138,674 Continuation-In-Part US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US10/287,949 Continuation-In-Part US20040102389A1 (en) 1995-10-26 2002-11-04 Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US10/664,668 Continuation-In-Part US20070203333A1 (en) 2001-11-30 2003-09-18 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/683,990 Continuation-In-Part US20040198682A1 (en) 2001-05-18 2003-10-10 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US10/712,633 Continuation-In-Part US20040220128A1 (en) 1995-10-26 2003-11-13 Nucleic acid based modulation of female reproductive diseases and conditions
US10/712,633 Continuation US20040220128A1 (en) 1995-10-26 2003-11-13 Nucleic acid based modulation of female reproductive diseases and conditions
US10/726,236 Continuation-In-Part US20040142895A1 (en) 1995-10-26 2003-12-02 Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway

Publications (2)

Publication Number Publication Date
WO2002096927A2 WO2002096927A2 (en) 2002-12-05
WO2002096927A3 true WO2002096927A3 (en) 2003-02-20

Family

ID=27385212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017674 WO2002096927A2 (en) 1995-10-26 2002-05-29 Ribozyme based treatment of female reproductive diseases

Country Status (6)

Country Link
EP (1) EP1390385A4 (en)
JP (2) JP2005500025A (en)
AU (1) AU2002344237B8 (en)
CA (1) CA2448320A1 (en)
GB (1) GB0404461D0 (en)
WO (1) WO2002096927A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914533B (en) * 2003-08-28 2013-06-19 诺瓦提斯公司 Interfering RNA duplexes with blunt ends and 3' modifications
US9233113B2 (en) 2009-06-22 2016-01-12 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (en) 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2006203062B2 (en) * 2002-02-20 2009-03-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
ES2397060T3 (en) 2002-04-18 2013-03-04 Opko Pharmaceuticals, Llc Means and methods for specific modulation of target genes in the eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
DK2284266T3 (en) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc SIRNA MOLECULE MOD TP53
FI1897548T4 (en) * 2003-02-28 2024-09-03 The Johns Hopkins University T cell regulation
JP2006521111A (en) * 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド Polypeptide compounds for inhibiting angiogenesis and tumor growth and applications thereof
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase inhibitor diagnosis and therapy
WO2005007853A2 (en) * 2003-06-06 2005-01-27 Senesco Technologies, Inc. Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
EP1687410A4 (en) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1711510A4 (en) * 2004-02-05 2008-11-26 Intradigm Corp Rnai therapeutics for treatment of eye neovascularization diseases
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2006004795A2 (en) * 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
US20060115455A1 (en) * 2004-10-22 2006-06-01 Reed Kenneth C Therapeutic RNAi agents for treating psoriasis
EP1833966A2 (en) * 2004-12-14 2007-09-19 National Institute of Immunology Dnazymes for inhibition of japanese encephalitis virus replication
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1877065A4 (en) 2005-04-12 2010-12-22 Intradigm Corp Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
JP2009537606A (en) * 2006-05-25 2009-10-29 ノバルティス アクチエンゲゼルシャフト Tyrosine kinase inhibitor
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
ES2655079T3 (en) 2009-09-10 2018-02-16 Merck Sharp & Dohme Corp. Use of IL-33 antagonists to treat fibrotic diseases
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
WO2012015775A2 (en) 2010-07-28 2012-02-02 Dharmacon, Inc. Sirna targeting vegfa and methods for treatment in vivo
JP6106085B2 (en) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Single-stranded RNAi agent containing an internal non-nucleic acid spacer
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR20230132635A (en) * 2013-05-22 2023-09-15 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 Extended release of neuregulin for treating heart failure
CN103627709A (en) * 2013-12-06 2014-03-12 孙仑泉 Deoxyribozyme capable of suppressing genetic expression of vascular endothelial growth factor
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004819A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004819A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARRY T.J. ET AL.: "Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA", NUCLEIC ACIDS RESEARCH, vol. 27, no. 13, 1999, pages 2569 - 2577, XP002956534 *
See also references of EP1390385A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914533B (en) * 2003-08-28 2013-06-19 诺瓦提斯公司 Interfering RNA duplexes with blunt ends and 3' modifications
US9233113B2 (en) 2009-06-22 2016-01-12 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases

Also Published As

Publication number Publication date
JP2009000106A (en) 2009-01-08
AU2002344237B2 (en) 2008-10-23
JP2005500025A (en) 2005-01-06
AU2002344237B8 (en) 2008-11-06
WO2002096927A2 (en) 2002-12-05
CA2448320A1 (en) 2002-12-05
EP1390385A2 (en) 2004-02-25
EP1390385A4 (en) 2004-11-24
GB0404461D0 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
WO2002096927A3 (en) Ribozyme based treatment of female reproductive diseases
KR102527941B1 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
Shen et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
EP2345718A3 (en) Compositions and methods for siRNA inhibition of angiogenesis
EP2636739B1 (en) iRNA agents targeting VEGF
JP2022061991A (en) Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2003070910A3 (en) INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
Kobayashi et al. Smad3 mediates TGF-β1 induction of VEGF production in lung fibroblasts
CN107106592A (en) Rnai agent for P21 Gene regulations
WO2002097114A3 (en) Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US8741870B2 (en) Axl receptor tyrosine kinase aptamer inhibitor for use in therapy
WO2004048525A3 (en) Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
WO2004042024B1 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
WO2004094606A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
CA2804847A1 (en) Sirna targeting vegfa and methods for treatment in vivo
JP2018531046A5 (en)
Arcaro et al. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells
Mangala et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy
Susantad et al. siRNA-mediated silencing of the 37/67-kDa high affinity laminin receptor in Hep3B cells induces apoptosis
EP1767632A3 (en) A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
Klein et al. Epidermal growth factor upregulates endometrial CYR61 expression via activation of the JAK2/STAT3 pathway
CN115151263A (en) Aptamers and uses thereof
DAI et al. Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim‐2 inhibited proliferation of DU‐145 cells
Huang et al. Estrogen receptor β agonist diarylpropionitrile inhibits lipopolysaccharide-induced regulated on activation normal T cell expressed and secreted (RANTES) production in macrophages by repressing nuclear factor κB activation
KR101292924B1 (en) Recombinant Vector Containing siRNA Targeing GCH1 and Pharmaceutical Composition for Attenuating Neuropathic Pain Comprising The Same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10287949

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10664668

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10712633

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002344237

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002752028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2448320

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003500106

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002752028

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002752028

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10664668

Country of ref document: US